Sam Fazeli

speaker

906 appearances 5 recordings 1 series first heard Oct 2025 last heard 31 Mar

Sam Fazeli’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Fosun Pharma’s Drive Beyond China · 17 Nov 2025 podcast

So that's going to be interesting.

And it does seem to me that you don't want to go and take on the king, if you want to call it, Keytruda, but to go at it in a very measured way rather than going into non-small cell lung cancer, Keynote 181 head-to-head.

But I'm looking forward to that.

I did see the press release from Henleus.

In fact, my colleagues are thinking a little bit more about it.

And so maybe when we speak again, maybe at ESMO or just after ESMO, we can have a little bit more understanding of how that data is potentially going to look or what at least the bar is.

But we're very excited by that.

So congratulations on that news too.

Oh, thank you.

No, no, I'm really intrigued by this molecule, as you can tell.

The next one I thought we could touch on is the CDK4-6.

Now, where would you put that?

Which bucket would you put that in?

I know it's not a bio, but is it a beta or a same or how would you classify that drug?

In terms of potential outside of China, of course, the complication potentially is that iBrands is heading for genericization.

And you've also got two pretty hefty competitors in the forms of Qiskali and iBrands.

Palbociclib.

So we have palbociclib, ribociclib, etc.

So anyway, we're in a world that's complicated.

But I often find that drugs that do have better CNS penetration do have an opportunity to really take hold when you've got a disease where CNS metastasis is a significant part of it.

Showing 601–620 of 906 · page 31 of 46